Search PubMed⌕ Search

Biomedical subjects

C J Papadatos

Publications and source records attributed to C J Papadatos.

14 recordsLinked to original sources
PubMed1982

Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics.

We studied the pharmacokinetics and efficacy of cefotaxime in 32 neonates with severe gram-negative infections. Many of these patients had been treated unsuccessfully with combinations of antibiotics. Eighty-one percent of these patients were cured, 6% improved, and 13% had treatment failures; there were three deaths. Eighteen patients received cefotaxime alone; 16 were cured and two improved. These data indicate an efficacy of cefotaxime sufficient to warrant more rigorous future trials. The elimination half-life of cefotaxime ranged from 2.0 +/- 0.4 hours in term neonates more than one week of age to 5.7 +/- 0.8 hours in preterm neonates less than one week of age. A volume of distribution of approximately 0.63 L was similar for all infants irrespective of age and maturity. These kinetic data can be used in design of future therapeutic regimens in more rigidly controlled trials assessing indications for cefotaxime therapy in neonates. We recommend dosing as follows, using a dose of 25 mg/kg: every 12 hours for preterm infants less than one week of age, every 8 hours for preterm infants one to four and term infants less than one week of age, and every 6 hours for term infants more than one week of age.

Bacterial Infections↗
PubMed1982

Syndrome of osteoporosis with pseudoglioma.

a 12 1/2-year-old boy with the rare autosomal recessive syndrome of osteoporosis with pseudoglioma is reported. Pertinent laboratory findings included osteoporotic lesions of the skeleton and calcification of the left lens. He was hypotonic and presented atrophic globes with opacities of the lenses. His psychomotor development was normal. Parental consanguinity is not excluded.

Brain Diseases↗
PubMed1982

Digital and palmar dermatoglyphics in Greeks.

The present study presents the dermatoglyphic frequencies of two samples from Greece. The first was obtained from adult male and female inhabitants of the island of Salamis. The second is a sample of school children from various parts of Greece. Comparisons of the dermatoglyphic frequencies of the two sample showed no differences among males. Female comparisons resulted in significant differences in digital pattern frequencies, modal types of the D line and Sydney creases. These three significant differences among females only, were not considered sufficient to provide dermatoglyphic discrimination between the two to provide dermatoglyphic discrimination between the two samples and therefore were pooled into one Greek Sample. In general the dermatoglyphic frequencies of the present Greek sample fell within the range of, and very close to the mean of, other Caucasian populations. Notable differences were observed, however, in the frequencies of accessory axial triradii and complete Sydney creases in both of which the Greeks had higher frequencies.

Adolescent↗
PubMed1982

Are viral studies indicated in juvenile-onset diabetes?

Recent observations have shown that insulin-dependent diabetes (JOD) may be the result of autoimmunity causing more or less rapid pancreatic isle cell destruction. This autoimmune process may be initiated in individuals who are genetically vulnerable to specific virus action. Several viruses have been implicated as causing JOD. Rubella and mumps viruses were the first viruses to be proved diabetogenic. A few years ago Coxsackie B viruses were added to the list. A prospective study of all new diabetics was undertaken in order to clarify the association of viral illness with JOD. 45 new insulin-dependent diabetics were studied (complement fixation, neutralizing antibodies or hemagglutination inhibition) within 3 days following admission. Screening for viral illnesses included the study for antibodies to the following: psittacosis, mycoplasma, Q fever, mumps, measles, herpes, CMV, rubella and chickenpox. Control bloods matched for sex, age, season and year with patients were obtained from individuals screened for viral illnesses during the same period. 18 JOD patients had antibodies against various Coxsackie B viruses. 4 patients had elevated rubella antibody titers.

Adenovirus Infections, Human↗
PubMed1981

Passage of cephalosporins and amoxicillin into the breast milk.

The concentrations of five cephalosporins and amoxicillin in breast milk were studied in 42 voluntarily participating lactating mothers using standard assay methods. Each mother received one single dose of 1 g of either an orally or intravenously administered antibiotic. Amoxicillin, cephalexin, and cefadroxil were given orally, and peak milk concentrations averaged 0.81 +/- 0.33 microgram/ml at 5 hours, 0.50 +/- 0.23 microgram/ml at 4 hours, and 1.64 +/- 0.73 microgram/ml at 6 hours, respectively. Cephalothin, cephapirin and cefotaxime were given as an i.v. bolus injection, and peak milk concentrations at 2 hours averaged 0.47 +/- 0.14 microgram/ml, 0.43 +/- 0.16 microgram/ml and 0.32 +/- 0.09 microgram/ml, respectively. The high concentrations of cefadroxil can be explained by its low rate of elimination and higher fat solubility. Milk/serum ratios for all antibiotics were increasing as serum concentrations were diminishing, especially with cephalothin and cephapirin whose serum concentrations are rapidly declining. The significance of bactericidal concentrations in breast milk remains to be evaluated.

Administration, Oral↗
PubMed1981

Clinical pharmacology of cefotaxime in pediatric patients.

Cefotaxime is a new cephalosporin with a spectrum of activity which may make it appropriate for use in pediatric patients. In 33 infants and children, administration of cefotaxime resulted in cure or improvement in 97% of patients, with eradication of 94% of isolated pathogens. Toxicity was minimal. The disposition of cefotaxime in this age group was similar to that reported for adults, with an elimination half-life of approximately 1.5 h, a volume of distribution of 1 liter/kg, a total serum clearance of 10 ml/min per kg, and a renal clearance of 6 ml/min per kg.

Bacterial Infections↗
PubMed1980

Antibacterial activity of HR-756, cefoxitin and cefuroxine against multiply antibiotic-resistant strains of Enterobacteriaceae and Pseudomonas aeruginosa.

The in vitro antibacterial activity of HR-756 compared to cefoxitin and cefuroxime. 122 multiresistant clinical isolates including Enterobacteriaceae (104) and P. aeruginosa (18), which present particular problems in antibiotic chemotherapy, were selected for study. HR-756 inhibited all the stains of S. marcescens, P. mirabilis and indole-positive Proteus spp. at a concentration of 1,3 and 12 micrograms/ml, respectively; beta-lactamase-producing strains were also susceptible. 90% of K. pneumoniae and more than half of the Enterobacter and P. aeruginosa were inhibited from the drug at a concentration 16 microgram/ml. Cefoxitin and cefuroxime were less active than HR-756. Cefoxitin was more effective against S. marcescens and P. mirabilis while the same was the case with cefuroxime against K. pneumoniae strains. The greater efficiency of HR-756 over cefoxitin and cefuroxime against these multiply resistant isolates seems to be due not only to its indifference to the beta-lactamases but also to its easier penetrability into the bacterial cell.

Bacteria↗
PubMed1979

Pharmacokinetics of amikacin in infants and pre-school children.

The pharmacokinetic properties of amikacin sulfate in infants and children aged from three weeks to 6 years were studied during treatment with doses of 7.5 mg/kg every 12 hours using standard assay methods and technique of two compartment open model kinetic analysis. Peak serum concentrations of amikacin were measured 30 or 60 min after the first intramuscular injection. These ranged from 11.8 microgram/ml to 23 microgram/ml in infants and from 9.0 microgram/ml to 29 microgram/ml in children. Five minutes after the first intravenous bolous injection they varied from 16 microgram/ml to 29.8 microgram/ml in infants and from 34 microgram/ml to 42 microgram/ml in children. Twelve hours after injection serum concentrations were less than 0.8 microgram/ml in all patients. Mean serum half-lives of amikacin in infants and children were 2.1 hours and 2.0 hours after intramuscular, and 2.2 and 2.0 hours after intravenous administration respectively. No evidence of accumulation was observed after four days treatment. The amount of antibiotic recovered within 12 hours from the urine in all patients ranged from 34.5 to 65% of an intramuscular dose, and from 45.8 to 63.3% of an intravenous dose. The dosage regime of 7.5 mg/kg body weight given every 12 hours should be safe and effective for the treatment of infections in the age groups studied.

Age Factors↗
PubMedDate not supplied

Guidelines for medical research in children.

Nearly everyone agrees that violations in research occur. Nobody knows how often. But if Pediatrics is to progress children must be the subjects of research carried out in an acceptable way. The following guidelines should be followed in childhood experimentation: (1) Research should not be done on children if the same investigation can be done in adults. (2) All research projects must be evaluated by ethics committees having as members lay people and investigators possessing the qualities of competence and judgement. (3) The degree of benefit from a research procedure should be assessed against the risk of disturbance, discomfort or pain. (4) Statements regarding consent are meaningless and consent is still only partially informed. Although a parental signature does not mean that consent is informed, nevertheless parental consent must still remain as a key requirement in childhood experimentation.

Advisory Committees↗